The Slo-Niacin trial. A trial of phosphate lowering agent slo-Niacin in patients on haemodialysis.

Phase 3

Completed

• Conditions: End stage renal failure.; Chronic Kidney disease - mineral bone disorder.; Hyperphosphataemia.; Renal and Urogenital - Kidney disease; Metabolic and Endocrine - Other metabolic disorders

• Registration Number: ACTRN12611000500954
• Lead Sponsor: Dr. Ken-Soon Tan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-05-13
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

1. Adult patients with end stage renal failure on maintenance haemodialysis.
2. Patients with hyperphosphataemia in context of the above.

Exclusion Criteria

1. Patients unable to give informed consent.
2. Pregnant patients.
3. Patients enrolled in other trials of medication.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum phosphate, measured weekly[24 weeks (duration of trial)]

Secondary Outcome Measures

Name	Time	Method
Safety and tolerability of active treatment compared to placebo.<br><br>1. Presence of side effects attributable to niacin: flushing, intradialytic hypotension, gastrointestinal upset. Monitored weekly by patient assessment.<br><br>2. Presence of hepato-toxicity: liver funciton tests monitored weekly.[24 weeks (duration of trial)]